3204 related articles for article (PubMed ID: 23627249)
1. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
Ruiz AD; Daniels KR
Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
[TBL] [Abstract][Full Text] [Related]
3. Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK; Pinson B; Price C
Int J Pharm Compd; 2008; 12(4):295-304. PubMed ID: 23969765
[TBL] [Abstract][Full Text] [Related]
4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
5. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women.
Matthews KA; Wing RR; Kuller LH; Meilahn EN; Plantinga P
Arch Intern Med; 1994 Oct; 154(20):2349-55. PubMed ID: 7944857
[TBL] [Abstract][Full Text] [Related]
6. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
[TBL] [Abstract][Full Text] [Related]
7. DHEA, important source of sex steroids in men and even more in women.
Labrie F
Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
[TBL] [Abstract][Full Text] [Related]
8. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
Holtorf K
Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
[TBL] [Abstract][Full Text] [Related]
9. Testosterone addition to estrogen therapy - effects on inflammatory markers for cardiovascular disease.
Kocoska-Maras L; Hirschberg AL; Byström B; Schoultz BV; Rådestad AF
Gynecol Endocrinol; 2009 Dec; 25(12):823-7. PubMed ID: 19906002
[TBL] [Abstract][Full Text] [Related]
10. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
Araújo DA; Farias ML; Andrade AT
Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
[TBL] [Abstract][Full Text] [Related]
11. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
12. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
13. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
15. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
[TBL] [Abstract][Full Text] [Related]
17. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
Genazzani AR; Cappagli B; Ciaponi M
Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
[TBL] [Abstract][Full Text] [Related]
18. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study.
Piltonen T; Puurunen J; Hedberg P; Ruokonen A; Mutt SJ; Herzig KH; Nissinen A; Morin-Papunen L; Tapanainen JS
Hum Reprod; 2012 Oct; 27(10):3046-56. PubMed ID: 22811306
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
20. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
Krapf JM; Simon JA
Maturitas; 2009 Jul; 63(3):213-9. PubMed ID: 19487090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
